Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05226598 · ClinicalTrials.gov registry record · Phase 3
Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007)
A Phase 3 study, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 3
- Development phase
- 739
- Enrollment target
NCT05226598 is a Phase 3 study that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 739 participants.
The verdict
NCT05226598, a Phase 3 study, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 739 participants
- Enrollment target
Study Summary
The primary hypothesis is that pembrolizumab/vibostolimab (MK-7684A) in combination with chemotherapy is superior to pembrolizumab in combination with chemotherapy with respect to overall survival (OS) in participants with programmed cell death-ligand 1 (PD-L1) tumor proportion score (TPS) ≥1%.
Interventions
- DRUG Carboplatin
- DRUG Cisplatin
- DRUG Paclitaxel
- DRUG Nab-paclitaxel
- BIOLOGICAL Pembrolizumab/Vibostolimab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 739 participants |
| Start Date | 2022-03-24 |
| Est. Completion | 2026-01-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05226598
The ClinicalTrials.gov registry entry for NCT05226598 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 739 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Carboplatin is the first listed.
NCT05226598 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05226598 about?
NCT05226598 is a clinical study titled "Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007)". The primary hypothesis is that pembrolizumab/vibostolimab (MK-7684A) in combination with chemotherapy is superior to pembrolizumab in combination with chemotherapy with respect to overall survival (OS) in participants with programmed cell death-ligand 1 (PD-L1) tumor proportion score (TPS) ≥1%.
What is the current status of trial NCT05226598?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 739 participants. The study started on 2022-03-24. Estimated completion is 2026-01-09.
What interventions are being tested in trial NCT05226598?
The interventions under investigation include: Carboplatin (DRUG), Cisplatin (DRUG), Paclitaxel (DRUG), Nab-paclitaxel (DRUG), Pembrolizumab/Vibostolimab (BIOLOGICAL).
Who is sponsoring clinical trial NCT05226598?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.